PHARMACEUTICAL | DRY EYE
Pipeline
Acoltremon (AR-15512) is an investigational drug and is not currently commercially available.
About Acoltremon
Acoltremon, a topical agonist of transient receptor potential melastatin 8 (TRPM8), is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease.
For more information about dry eye disease, please visit
Understanding Dry Eye.
Clinical Trials for Acoltremon
Pivotal studies for Acoltremon have been successfully completed.
For a comprehensive overview of the COMET clinical development program, please explore this interactive resource.
Scientific Publications and Abstracts
DRY EYE CLINICAL TRIAL
Acoltremon (AR-15512) is an agonist of the transient receptor potential melastatin 8 receptor.